Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Myricx Bio

- PMLiVE

Novartis to acquire Myricx Bio in deal worth $1.5bn

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

- PMLiVE

Klick Health acquires Oxford PharmaGenesis

The move expands Klick’s scientific expertise in oncology and rare diseases

- PMLiVE

Zymeworks to acquire Theravance Biopharma in deal worth $929m

The acquisition will give the company access to a treatment for COPD

- PMLiVE

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

- PMLiVE

Biogen to acquire RayThera in $1bn deal

The acquisition will expand the company’s immunology pipeline

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly to acquire Curevo in deal worth $1.5bn

The acquisition will help build Lilly’s infectious disease portfolio

- PMLiVE

Novartis breaks ground on US radioligand therapy site

The construction is part of the company’s investment in US research and manufacturing

- PMLiVE

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Catalyst Pharmaceuticals is focused on novel medicines for rare diseases

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

- PMLiVE

Biogen to acquire Apellis in $5.6bn deal

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links